NR1H3 and metabolic dysfunction-associated steatotic liver disease: A synthetic agonist T0901317-dependent LXRα target genes and T0901317-induced TG accumulation were inhibited by 117 in primary hepatocytes, further suggesting it as a potential antilipogenic agent to treat NAFLD (Oh et al., 2015a).